SPA
NVAX icon

Sherbrooke Park Advisers’s Novavax NVAX Stock Holding History

Sherbrooke Park Advisers’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$82.7K Buy
12,306
+1,711
+16% +$12.9K 0.21% 139
2025
Q3 		$91.9K Sell
10,595
-10,085
-49% -$78.5K 0.04% 456
2025
Q2 		$130K Buy
20,680
+8,437
+69% +$55.9K 0.06% 437
2025
Q1 		$78.5K Buy
+12,243
New +$101K 0.04% 533

Other funds holding NVAX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sherbrooke Park Advisers's NVAX Position: Q4 2025 in Review

Sherbrooke Park Advisers increased its Novavax (NVAX) stake by 16% in Q4 2025, buying an estimated $12.9K and bringing the position to 12,306 shares worth $82.7K. The position accounts for 0.21% of the portfolio, ranked #139.

Sherbrooke Park Advisers first reported a position in NVAX in Q1 2025 and has held it in 4 quarters since. The position peaked at $130K in Q2 2025. 235 funds tracked by Wall St. Rank hold NVAX as of Q4 2025.

  • Sherbrooke Park Advisers held 12,306 shares of Novavax worth $82.7K as of Q4 2025.
  • Sherbrooke Park Advisers bought 1,711 Novavax shares in Q4 2025, an estimated $12.9K.
  • Novavax made up 0.21% of Sherbrooke Park Advisers's portfolio in Q4 2025, its #139 holding.
  • Sherbrooke Park Advisers first reported a position in Novavax in Q1 2025 and has held it in 4 quarters since.
  • Sherbrooke Park Advisers's Novavax position peaked at $130K in Q2 2025.
  • 235 funds tracked by Wall St. Rank held Novavax as of Q4 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.